Clinical Trials Logo

Clinical Trial Summary

The study investigates the regulation of muscle glucose utilization during exercise and enhanced insulin sensitivity in recovery from exercise. This will be investigated in lean control subjects and obese insulin resistant subjects.


Clinical Trial Description

The subjects will perform two trials (trial A and B). Trial A: During trial A the study subject will eat a morning meal at 6:00 a.m. corresponding to 5% of the daily energy requirements and will arrive at the research laboratory at 8:00 a.m. It is requested that the study subject will arrive in a car or with public transportation. After arrival the study subject will rest for 1 hour and at that time catheters are inserted in both femoral veins and the femoral artery in one of the legs. At 9:00 a.m. the study subjects will perform one-leg knee extension exercise for 1 hour at an intensity of 80% of maximal work capacity. In this work protocol there are inserted 3 intervals of 5 minutes duration where the study subject works at 100% of maximal intensity with the purpose of securing a full activation/recruiting of all muscle fibers. Muscle biopsies from the m. vastus lateralis muscle in both legs will be taken before (at 8.45 a.m.), immediately after (at 10:00 a.m.) and 2 hours after conclusion of exercise (at 12:00 p.m.) (in total of 6 biopsies). Pulmonary oxygen uptake is measured with the use of an online system before, during and after exercise and is used for determination of substrate metabolism. Blood samples from the femoral veins in both legs and the femoral artery in one of the legs are drawn before (at 8:20 a.m., 8:40 a.m. and 9:00 a.m.), during exercise (at 9:20 a.m., 9:40 a.m. and 10:00 a.m.) and during the recovery period after exercise (at 10:10 a.m., 10:30 a.m., 11:00 a.m., 11:30 a.m. and 12:00 p.m.). At the same time blood flow is measured in the femoral arteries in both legs with the use of Doppler technique. Determination of arteriovenous difference (AV difference) by simultaneous measurement of blood flow enables us to calculate skeletal muscle glucose uptake and uptake/release of relevant substances (proteins, peptides and metabolites etc.). The experimental part of trial A is completed at 12:00 p.m. The study subject will be given food and drink and will be observed for one hour before they may leave the research laboratory. Trial B: During test trial B the study subjects will eat a morning meal at 6:00 a.m. corresponding to 5% of the daily energy requirements and will arrive at the research laboratory at 8:00 a.m. It is requested that the study subject will arrive in a car or with public transportation. During trial B the study subjects will perform the same one-leg knee extension exercise protocol as in trial A. At 9:00 a.m. the study subject starts performing one-leg knee extension exercise for 1 hour at 80% of maximal work capacity with 3 intervals of 5 minutes duration where the load is at 100% of maximal work capacity. This work protocol ensures full activation/recruiting of all muscle fibers. After the kicking exercise is completed the study subject will rest in supine position for 6 hours. At the beginning of this resting period catheters are inserted in the femoral veins in both legs and in the femoral artery in one leg. Also catheters are inserted in each forearm vein (antecubital veins) for intravenous infusion of insulin, glucose and stable 13C(u)-glucose. Intravenous infusion of 13C(u)-glucose is started 2 hours after conclusion of exercise in order to achieve a 10% enrichment of blood glucose. 4 hours after cessation of exercise a hyperinsulinemic euglycemic clamp of 120 minutes duration is started. This implies intravenous infusion of insulin and glucose for 120 minutes in order to determine insulin sensitivity for glucose uptake and metabolism of glucose. The clamp is started with a bolus injection of insulin (9.0 mU/kg) followed by a constant infusion (1.42 mU/kg/min). Simultaneously glucose infusion rate will be adjusted so that euglycemia is maintained. Immediately before, after 30 minutes and after 120 minutes of insulin infusion a muscle biopsy is taken from the vastus lateralis muscle in both legs (a total of 6 biopsies). Blood samples from both femoral veins and one femoral artery are taken before (at 12:00 p.m., 12:30 p.m., 1:00 p.m., 1:30 p.m. and 2:00 p.m.) and during (at 2:15 p.m., 2:30 p.m., 2:45 p.m., 3:00 p.m., 3:15 p.m., 3:30 p.m., 3:45 p.m. and 4:00 p.m.) the hyperinsulinemic euglycemic clamp. Simultaneously blood flow is measured in both femoral arteries with use of Doppler technique. Determination of arteriovenous difference (AV difference) by simultaneous measurement of blood flow enables us to calculate glucose uptake and uptake/release of relevant substances (proteins, peptides and metabolites etc.). Indirect calorimetry for determination of whole body metabolism is measured concomitantly, starting 2 hours after conclusion of exercise. The experimental part of trial B is concluded at 4:00 p.m. The study subjects receive food and drink and are observed for one hour before they may leave the research laboratory. Muscle biopsies and blood samples from trial A and B are stored in a locked -80ºC freezer. Muscle samples and blood samples will subsequently be used for miscellaneous analyses described under background. The trials (A and B) will be carried out in a randomized order and will be separated by a minimum of 14 days. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04178603
Study type Interventional
Source University of Copenhagen
Contact
Status Completed
Phase N/A
Start date July 5, 2018
Completion date September 1, 2020

See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A